These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 20160479

  • 1. Epstein-Barr virus in Burkitt's lymphoma: a role for latent membrane protein 2A.
    Bieging KT, Swanson-Mungerson M, Amick AC, Longnecker R.
    Cell Cycle; 2010 Mar 01; 9(5):901-8. PubMed ID: 20160479
    [Abstract] [Full Text] [Related]

  • 2. Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis.
    Ikeda M, Hayes CK, Schaller SJ, Longnecker R.
    Blood Adv; 2022 Jul 26; 6(14):4283-4296. PubMed ID: 35605249
    [Abstract] [Full Text] [Related]

  • 3. Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.
    Cen O, Longnecker R.
    Mol Cancer Ther; 2011 Apr 26; 10(4):679-86. PubMed ID: 21282357
    [Abstract] [Full Text] [Related]

  • 4. Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis.
    Bieging KT, Amick AC, Longnecker R.
    Proc Natl Acad Sci U S A; 2009 Oct 20; 106(42):17945-50. PubMed ID: 19815507
    [Abstract] [Full Text] [Related]

  • 5. Two Pathways of p27Kip1 Degradation Are Required for Murine Lymphoma Driven by Myc and EBV Latent Membrane Protein 2A.
    Sora RP, Ikeda M, Longnecker R.
    mBio; 2019 Apr 16; 10(2):. PubMed ID: 30992353
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma?
    Allday MJ.
    Semin Cancer Biol; 2009 Dec 16; 19(6):366-76. PubMed ID: 19635566
    [Abstract] [Full Text] [Related]

  • 8. Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis.
    Bultema R, Longnecker R, Swanson-Mungerson M.
    Oncogene; 2009 Mar 19; 28(11):1471-6. PubMed ID: 19182823
    [Abstract] [Full Text] [Related]

  • 9. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
    Niedobitek G, Agathanggelou A, Rowe M, Jones EL, Jones DB, Turyaguma P, Oryema J, Wright DH, Young LS.
    Blood; 1995 Jul 15; 86(2):659-65. PubMed ID: 7605996
    [Abstract] [Full Text] [Related]

  • 10. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
    De Leo A, Arena G, Stecca C, Raciti M, Mattia E.
    Mol Cancer Res; 2011 Oct 15; 9(10):1346-55. PubMed ID: 21856773
    [Abstract] [Full Text] [Related]

  • 11. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
    Kelly GL, Milner AE, Baldwin GS, Bell AI, Rickinson AB.
    Proc Natl Acad Sci U S A; 2006 Oct 03; 103(40):14935-40. PubMed ID: 17001014
    [Abstract] [Full Text] [Related]

  • 12. The LCR of EBV makes Burkitt's lymphoma endemic.
    Niller HH, Salamon D, Banati F, Schwarzmann F, Wolf H, Minarovits J.
    Trends Microbiol; 2004 Nov 03; 12(11):495-9. PubMed ID: 15488390
    [Abstract] [Full Text] [Related]

  • 13. The investigation of Epstein-Barr viral sequences in 41 cases of Burkitt's lymphoma from Egypt: epidemiologic correlations.
    Anwar N, Kingma DW, Bloch AR, Mourad M, Raffeld M, Franklin J, Magrath I, el Bolkainy N, Jaffe ES.
    Cancer; 1995 Oct 01; 76(7):1245-52. PubMed ID: 8630905
    [Abstract] [Full Text] [Related]

  • 14. The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMP1, and its expression promotes the survival of a Burkitt's lymphoma cell line.
    D'Souza B, Rowe M, Walls D.
    J Virol; 2000 Jul 01; 74(14):6652-8. PubMed ID: 10864681
    [Abstract] [Full Text] [Related]

  • 15. Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma.
    Fish K, Chen J, Longnecker R.
    Blood; 2014 Jan 23; 123(4):530-40. PubMed ID: 24174629
    [Abstract] [Full Text] [Related]

  • 16. EBV latent membrane protein 2A orchestrates p27kip1 degradation via Cks1 to accelerate MYC-driven lymphoma in mice.
    Fish K, Sora RP, Schaller SJ, Longnecker R, Ikeda M.
    Blood; 2017 Dec 07; 130(23):2516-2526. PubMed ID: 29074502
    [Abstract] [Full Text] [Related]

  • 17. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis.
    Niller HH, Salamon D, Ilg K, Koroknai A, Banati F, Bauml G, Rucker O, Schwarzmann F, Wolf H, Minarovits J.
    Med Sci Monit; 2003 Jan 07; 9(1):HY1-9. PubMed ID: 12552250
    [Abstract] [Full Text] [Related]

  • 18. Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells.
    Renouf B, Hollville E, Pujals A, Tétaud C, Garibal J, Wiels J.
    Leukemia; 2009 Sep 07; 23(9):1557-63. PubMed ID: 19421231
    [Abstract] [Full Text] [Related]

  • 19. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata.
    Komano J, Sugiura M, Takada K.
    J Virol; 1998 Nov 07; 72(11):9150-6. PubMed ID: 9765461
    [Abstract] [Full Text] [Related]

  • 20. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, Powis S, Belich M, Croom-Carter D, Lee S, Burrows SR.
    Eur J Immunol; 1995 May 07; 25(5):1374-84. PubMed ID: 7774641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.